Trials in Relapsed/Refractory Multiple Myeloma A conversation on current trails with multiple myeloma including CANDOR and IKEMA; understanding the role of anti-CD38 monoclonal antibody in the treatment of relapsed/refractory multiple myeloma. Website: https://www.onclive.com Twitter: https://twitter.com/OncLive Facebook: https://www.facebook.com/OncLive/ LinkedIn: https://www.linkedin.com/company/onclive

Pomalidomide in Refractory Multiple Myeloma In this segment, Noopur Raje, MD, Sagar Lonial, MD, and Ann McNeill, RN, APN, discuss the role of pomalidomide in therapy for patients with multiple myeloma, as well as the toxicities and adverse reactions associated with pomalidomide therapy. Get more expert insight, at http://www.onclive.com/insights/myeloma

Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) Background: MM inevitably relapses and becomes refractory to treatment, representing a patient (pt) population with unmet needs. Teclistamab (JNJ-64007957) is a bispecific BCMA x CD3 […]

How is nonsecretory multiple myeloma diagnosed? Dr. Philippe Moreau discusses diagnosing multiple myeloma in a patient that is not secreting proteins but presents with CRAB symptoms. Join our online communities to begin receiving free continuing medical education (CME) credit today! Managing Myeloma: http://www.managingmyeloma.com/ Managing Hodgkin Lymphoma: http://www.managinghodgkinlymphoma.com/ Managing MDS: http://www.managingmds.com/ Managing CML: http://www.managingcml.com/ Partners in […]

Ask the Multiple Myeloma Experts Summary: The current standard of care for patients with multiple myeloma is high dose chemotherapy and an autologous stem cell transplant. Although an autologous transplant is not a cure, maintenance therapy with various drugs can control myeloma in many patients for several years. Panelists: Jens Hillengass MD, Chief of Myeloma, […]